Department of Biochemistry, Rush University Medical Center, Cohn Research BD 516, 1735 West Harrison Street, Chicago, IL 60612, USA.
Arthritis Res Ther. 2011;13(5):R165. doi: 10.1186/ar3485. Epub 2011 Oct 13.
Degeneration of the interverterbral disk is as a cause of low-back pain is increasing. To gain insight into relationships between biological processes, structural alterations and behavioral pain, we created an animal model in rats.
Disk degeneration was induced by removal of the nucleus pulposus (NP) from the lumbar disks (L4/L5 and L5/L6) of Sprague Dawley rats using a 0.5-mm-diameter microsurgical drill. The degree of primary hyperalgesia was assessed by using an algometer to measure pain upon external pressure on injured lumbar disks. Biochemical and histological assessments and radiographs of injured disks were used for evaluation. We investigated therapeutic modulation of chronic pain by administering pharmaceutical drugs in this animal model.
After removal of the NP, pressure hyperalgesia developed over the lower back. Nine weeks after surgery we observed damaged or degenerated disks with proteoglycan loss and narrowing of disk height. These biological and structural changes in disks were closely related to the sustained pain hyperalgesia. A high dose of morphine (6.7 mg/kg) resulted in effective pain relief. However, high doses of pregabalin (20 mg/kg), a drug that has been used for treatment of chronic neuropathic pain, as well as the anti-inflammatory drugs celecoxib (50 mg/kg; a selective inhibitor of cyclooxygenase 2 (COX-2)) and ketorolac (20 mg/kg; an inhibitor of COX-1 and COX-2), did not have significant antihyperalgesic effects in our disk injury animal model.
Although similarities in gene expression profiles suggest potential overlap in chronic pain pathways linked to disk injury or neuropathy, drug-testing results suggest that pain pathways linked to these two chronic pain conditions are mechanistically distinct. Our findings provide a foundation for future research on new therapeutic interventions that can lead to improvements in the treatment of patients with back pain due to disk degeneration.
椎间盘退变是导致腰痛的一个原因,其发病率越来越高。为了深入了解生物过程、结构改变和行为疼痛之间的关系,我们在大鼠中建立了一个动物模型。
通过使用 0.5 毫米直径的微创手术钻从大鼠的腰椎(L4/L5 和 L5/L6)椎间盘去除髓核(NP)来诱导椎间盘退变。使用压力计测量受伤腰椎上外部压力引起的疼痛来评估原发性痛觉过敏的程度。对受伤椎间盘进行生化和组织学评估以及放射学检查。我们在该动物模型中通过给予药物来研究慢性疼痛的治疗调节。
NP 去除后,下背部出现压痛。手术后 9 周,我们观察到椎间盘损伤或退变,伴有蛋白聚糖丢失和椎间盘高度变窄。这些椎间盘的生物和结构变化与持续的疼痛过敏密切相关。高剂量吗啡(6.7mg/kg)可有效缓解疼痛。然而,高剂量普瑞巴林(20mg/kg),一种用于治疗慢性神经性疼痛的药物,以及抗炎药塞来昔布(50mg/kg;环氧化酶 2(COX-2)的选择性抑制剂)和酮咯酸(20mg/kg;COX-1 和 COX-2 的抑制剂)在我们的椎间盘损伤动物模型中均没有明显的抗痛觉过敏作用。
尽管基因表达谱的相似性表明与椎间盘损伤或神经病变相关的慢性疼痛途径可能存在重叠,但药物测试结果表明,与这两种慢性疼痛状况相关的疼痛途径在机制上是不同的。我们的研究结果为进一步研究新的治疗干预措施提供了基础,这些干预措施可能会改善因椎间盘退变导致的腰痛患者的治疗效果。